Effect of Human Immunodeficiency Virus Infection on the Incidence and Severity of Neurological Post-Acute Sequelae of COVID-19 (S21.009)

Abstract

<h3>Objective:</h3> To investigate whether HIV infection is an independent prognostic factor of neurological post-acute sequelae of COVID-19 (PASC). <h3>Background:</h3> HIV has been linked to an increase in severity of symptoms of PASC. <h3>Design/Methods:</h3> COVID-19 inpatients from a tertiary care center were collected and retrospectively studied for presence of neurological PASC symptoms, 4 weeks to up to 1 year after their first inpatient admission COVID-19. Patients with HIV and COVID-19 were compared to non-HIV COVID-19 patients. All demographic, nominal and inpatient data including length of stay, discharge, medications and lab data was compared. The proportion of patients reporting neurological PASC symptoms in HIV vs non-HIV patients with a history of COVID-19 were compared. <h3>Results:</h3> 277 patients who had an outpatient follow-up or were readmitted to the hospital were reviewed. 27 patients had HIV and 22 followed up. There was no significant difference in age between HIV and non-HIV groups (55.3±11.3 vs 52.5±18.5 p&gt;0.05) For HIV vs non-HIV patients with a history of COVID-19, numbness (18.2% vs 10.5%) paresthesias (9.1% vs 7.5%), brain fog or cognitive impairment (9.1% vs 6.7%), weakness (18.1% vs 27.1%), fatigue (31.2% vs 30.6%), headaches (18.1% vs 16.9%), changes in smell of taste (18.1% or 11.7), sleep issues or insomnia (13.6% vs 9.4%) and anxiety or depression (27.7% vs 18.0%) were reported between 4 weeks and 1 year after admission. Although there is an increased incidence of most neurological PASC symptoms in HIV compared to non-HIV, the difference did not reach significance. <h3>Conclusions:</h3> This preliminary analysis of COVID-19 patients with 1 year follow-up demonstrates that the incidence of neurological symptoms of PASC in HIV patients vs non-HIV patients did not significantly differ. The incidence reported in this study agrees with prior literature on the incidence of neurological PASC. Work is in progress expand the study size and control for concomitant neurological conditions. <b>Disclosure:</b> Mr. Jaffry has nothing to disclose. Mr. Mandava has nothing to disclose. Mr. Jaffry has nothing to disclose. Mr. Ors has nothing to disclose. Miss Shaikh has nothing to disclose. Mr. Trivedi has nothing to disclose. Ms. Faiz has nothing to disclose. Mr. Gerges has nothing to disclose. Prof. Boufadel has nothing to disclose. Dr. Souayah has received publishing royalties from a publication relating to health care.